BioSpace News Archive

The two companies announced their exclusive collaboration that will harness Kumquat’s small molecule immuno-oncology platform’s capabilities to discover novel clinical candidates.

Nuvalent, Rallybio and Icosavax all began selling on the Nasdaq Exchange today.

Semglee was approved under the FDA’s 351(k) pathway, a biologics license application process. It ensures that the bio similarity is based on animal studies, clinical trials, and analytical studies.

Kaiser Permanente has reportedly filed a lawsuit against drug maker Merck for allegedly allowing a “pay-for-delay” scheme that cost the former millions of dollars.

Clinical-stage biotech company Vaxart announced Thursday that a second dose of its oral norovirus vaccine boosted immunity in clinical trial participants who had previously received the vaccine more than a year prior.

Three major pharmaceutical and biotechnology companies announce the success of their respective funding rounds to support future efforts.

Avian influenza can be defined as the disease caused by infection by the bird flu Type-A virus. These viruses are found commonly in aquatic birds and they can cause infection in domestic poultry and other species of birds.

Topas Therapeutics GmbH, a private biotechnology company developing immune tolerance-inducing drugs to treat and potentially cure a variety of autoimmune diseases, announced that the Company has successfully extended its Series B round with an additional €18 million raised, bringing the total for this financing to €40 million.

The life science company Sartorius Stedim Biotech acquired cell culture specialist Xell AG headquartered in Bielefeld, Germany.

Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, announced the appointment of Uz Stammberger, MD, as Chief Medical Officer.